Market Currents
Threshold Pharmaceuticals (THLD) jumps 13.5% after the FDA reaches an agreement for the Phase...
-
Tuesday, October 16, 2012, 9:01 AM ETThreshold Pharmaceuticals (THLD) jumps 13.5% after the FDA reaches an agreement for the Phase III trial of TH-302 for the treatment of pancreatic cancer. The study will be conducted by Germany's Merck, Threshold's partner in the development of TH-302. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
